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In this issue of Cell Stem Cell, the origin of multipotent hematopoietic cells present in the placenta has been
assessed in Ncx1/ embryos lacking a functional heart and circulation. Rhodes and colleagues (Rhodes
et al., 2008) found lymphoid progenitors in the placenta, as well as in dorsal aorta and yolk sac and vitelline
vessels, indicating that they arose in situ.The origin of hematopoietic stem cells
(HSCs) has been debated for decades
and remains a question of major interest.
It is well documented that HSCs appear
during a short time window during embry-
onic development, before or concomitant
to fetal liver colonization (reviewed in Cu-
mano and Godin, 2007) (Figure 1). In addi-
tion, there is no evidence for subsequent
waves of HSC generation beyond these
early points (Samokhvalov et al., 2007).
The microenvironment in which this pro-
cess occurs induces the specification of
a mesodermal progenitor into the hema-
topoietic lineage. Thus, the identification
of the sites in which HSC generation oc-
curs will pave the way to the
characterization of the speci-
fying signals that lead to the
formation of a HSC. This in-
formation will allow the ma-
nipulation of undifferentiated
cells for the production
in vitro of large numbers of
hematopoietic progenitors.
It is generally accepted that
the dorsal aorta, also desig-
nated para-aortic spanchno-
pleura (P-Sp) or aorta-go-
nads-mesonephros (AGM), is
a site of origin for HSC. The
experimental evidence point-
ing to other sites contributing
to the HSC pool, namely the
yolk sac, the vitellin/ompha-
lomesenteric vessels, and,
more recently, the placenta
(Gekas et al., 2005; Otters-
bach and Dzierzak, 2005), is
more controversial. The main
limitation of these analyses
comes from the active redis-
tribution of hematopoietic
progenitors to different tissues via the
circulating blood. The present work by
Rhodes and collaborators (Rhodes et al.,
2008) analyzes hematopoietic cells with
lymphoid differentiation potential isolated
from the placenta, dorsal aorta, and yolk
sac/vitelline vessels in Ncx1/ mice.
These mutants have a defect in the so-
dium/calcium pump 1 and thus have nei-
ther heartbeat nor blood circulation. The
presence of hematopoietic progenitors
with lymphoid potential in all three embry-
onic locations examined suggests that
the populations are generated in situ.
This conclusion is supported by the anal-
ysis of Runx1 and CD41 expression in
the placenta. Runx1 is a transcription
factor expressed in endothelial cells and
in emerging hematopoietic progenitors,
while CD41 is undetectable in endothe-
lium but coexpressed with Runx1 in
hematopoietic cells of midgestation em-
bryos. In Runx1-lacZ/+ embryos, lacZ+
cells are detected in the mesenchyme
that surrounds large vessels, in the wall
of chorioallantoic vessels, and in clusters
of cells in the lumen of the vessels. These
clusters are not seen in Runx1-deficient
embryos that do not develop HSC. The
observed lacZ+ cells present in the wall
and in the lumen of vessels coexpress
CD41, indicating they are hematopoietic
cells. Interestingly, while he-
matopoietic cells in the dorsal
aorta are not actively
undergoing cell division,
those found in the placenta
also express a marker of
mitotic cells, confirming pre-
vious studies that assign the
placenta as a particular en-
vironment for hematopoietic
cell expansion.
In normal embryos, circula-
tion is established at the 4–6
somite stage (E8.5), prior to
the detection of multipotent
cells. Ncx1/ mutants are
not viable after E10.5, and
therefore explants were ana-
lyzed between E8.5 and
E9.5. The authors isolated
cells with the capacity to
give rise in vitro to T cells
and possibly B progenitors
(CD19 expression is a more
reliable marker for B lineage
cells than B220, which is
also expressed by NK, DC,
Figure 1. A Schematic Representation of the Putative Sites
of Hematopoietic Cell Generation
It has been proposed that hematopoietic cells are independently generated in
the yolk sac (yellow), placenta (red), and large vessels (dorsal and vitelline aorta
[VA]). They circulate and colonize the fetal liver (teal) where fetal hematopoiesis
occurs. The fetal liver and placenta are the major sites for HSC expansion
(blue).Cell Stem Cell 2, March 2008 ª2008 Elsevier Inc. 197
Cell Stem Cell
Previewsand T cell progenitors) in all investigated
sites, namely the dorsal aorta, placenta,
and yolk sac, although this latter also con-
tains the vitellin vessels. Assuming that
the absence of circulation and conse-
quent hypoxia does not influence the
site and timing of hematopoietic cell gen-
eration, this study indicates that multiline-
age hematopoietic progenitors can origi-
nate independently from the dorsal
aorta, the placenta, and the territory com-
prising the yolk sac and vitellin arteries.
Only a limited fraction of the hemato-
poietic cells generated in the embryo
will become HSCs. Most progenitors are
rather restricted in their differentiation
potential and will either engage in the
erythrocyte or the myelo-monocytic line-
ages. A minority of cells are lympho-
myeloid progenitors and when placed
under the appropriate conditions will dif-
ferentiate into all hematopoietic lineages.
Of these populations, the first to appear
only display reconstitution capacity if in-
jected in newborn animals or in severely
immunocompromised recipients. In more
developed embryos, robust long-term
reconstituting multipotent cells can be
isolated. The unequivocal identification
of a HSC still requires demonstration of
multilineage potential at the single-cell
level as well as the capacity to reconsti-Directing Stem Ce
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Multipotent stem cells, whether somatic
or embryonic stem cell-derived, possess
a great capacity for tissue regeneration.
In clinical settings, the optimal route for
administration of stem cells depends on
the anatomy and the extent of damage
of the involved tissue or organ, offering a
198 Cell Stem Cell 2, March 2008 ª2008 Elstute the entire hematopoietic compart-
ment upon transfer. In vivo protocols
have been described that provide ade-
quate conditions for cells isolated at the
embryonic stages studied here to provide
long-term hematopoietic contribution
(Yoder et al., 1997; Cumano et al., 2001).
They involve either injection of cells in the
liver of newborn mice or intravenous
injection in B/T/NK-deficient mice. The
in vivo reconstitution capacity of the cells
detected in this study has not been
assessed, and therefore their HSC nature
has yet to be fully determined.
An expectation of this experimental
system is that, since cells are actively
dividing, in the absence of circulation the
newly generated hematopoietic cells
might accumulate in the placenta. Due
to the early lethality experienced by the
mutant mice used in this system, the tim-
ing of analysis is obviously constrained,
and the number of embryos obtained is
severely limiting. Nevertheless, the au-
thors endeavored to quantify cells present
in sections of the placenta of normal and
Ncx1 mutants. Mutant mice exhibit 5-
fold less hematopoietic progenitors than
the wild-type. This result indicates that
probably only a small fraction of hemato-
poietc multipotent progenitors normally
detected here are of placental origin andll Homing
an Diego, CA 92121, USA
ds partly on the delivery of stem cel
008) report that ex vivo fucosylation
d mesenchymal stem cells with ma
choice between two approaches: direct
local or intralesional implantation versus
systemic intravascular administration. Al-
though feasible for tissues with defined
anatomic boundaries, local implantation
is invasive, has associated procedure-re-
lated costs, and could result in significant
evier Inc.that the majority of cells observed in pre-
vious studies likely originate elsewhere.
The picture that emerges from this work
is that hematopoietic progenitors that
are generated during a short window in
gestation do so at multiple sites, including
the large vessels (aorta, vitellin vessels) or
vascular networks (the placenta and yolk
sac) in close connection to the endothelial
cell compartment.
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335–344.ls to the damaged area. Recently in
of surface CD44 promoted efficient
rrow vasculature and subsequent
morbidity. Moreover, this approach could
disrupt a highly complex and delicate
structure of the local regulatory microen-
vironment, i.e., the niche, causing addi-
tional traumatic injury and inflammation.
Another limitation for the local administra-
tion of stem cells is the multifocality of
